Navigation Links
/C O R R E C T I O N -- Clinical Therapeutics/
Date:9/10/2009

In the news release, "Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section" issued on 9 Sep 2009 08:30 GMT, by Clinical Therapeutics over PR Newswire, we are advised by a representative of the company that the Dateline has been changed from "Bridgewater, England" to "Bridgewater, New Jersey" and the contact number has been changed from +44(0)908-547-2094 to +1-908-547-2094 which were incorrectly transmitted by PR Newswire. Complete, corrected release follows:

, /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section, Clinical Therapeutics(http://www.clinicaltherapeutics.com/) seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to clinther@elsevier.com; click here for Information for Authors (http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +1-908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com


------

Clinical Therapeutics Announces the Addition of Michael G. Spigarelli, MD, PhD, as Editor for a Refocused Pediatric, Adolescent, & Maternal Therapeutics Section

BRIDGEWATER, England, September 9 /PRNewswire/ -- Clinical Therapeutics,( http://www.clinicaltherapeutics.com/) the world's premier, rapid-publication journal, is proud to announce the addition of Michael G. Spigarelli, MD, PhD, to our distinguished editorial board.

As section editor for the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section (formerly the Pediatric Research section), Dr. Spigarelli brings a wealth of knowledge and a strong background in addressing the issues surrounding these special populations. He completed his residency in internal medicine and pediatrics at the University of Michigan Medical Center in Ann Arbor and his fellowship in adolescent medicine at Cincinnati Children's Hospital Medical Center, where he currently remains on staff.

Pregnant women and children remain among the most vulnerable patients undergoing therapy today due to a lack of critical information on the safety, tolerability, and efficacy of pharmacotherapies indicated for them. As Dr. Spigarelli states in his inaugural editorial, "To date, most medications used in the treatment of illness in children have never been tested in them.... This lack of crucial information has important implications for a variety of stakeholders."

By refocusing the Pediatric, Adolescent, & Maternal Therapeutics (http://www.clinicaltherapeutics.com/ped.html) section, Clinical Therapeutics(http://www.clinicaltherapeutics.com/) seeks to become the premier venue for publication of clinical research in these special populations and serve as an international forum for the timely discussion of safe and effective drug therapies in neonates, infants, children, adolescents, and pregnant or lactating women.

"As Editor of this section, I encourage each of you to review your files for data already obtained but not yet published, for data from ongoing studies, and consider submitting those manuscripts to Clinical Therapeutics. Each additional piece of available data adds to the knowledge base needed to provide the best health care for pregnant women and children."

An example of important pediatric information published by the journal is the supplemental issue on Conquering Pain: The Hidden Cost of Immunization sponsored by the Canadian Institutes of Health Research and the SickKids Foundation. Also highlighting the journal's commitment to fostering publication of scientific research related to these special populations is the upcoming focus issue on vaccines.

Articles can be submitted online or directly to clinther@elsevier.com; click here for Information for Authors (http://www.clinicaltherapeutics.com/ifa3.html).

For more information about this press release and Clinical Therapeutics, contact Julie E. Artim at:

    Phone: +44(0)908-547-2094
    Email: ELSRapidPubs@Elsevier.com
    Website: ElsRapidPubs.com



'/>"/>
SOURCE Clinical Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today ... fiscal year ended September 30, 2016. ... , , SQI ... company that develops and commercializes proprietary technologies and products for advanced ... revenues of $1.4 million more than tripling prior years revenue. ...
(Date:12/6/2016)... ... December 06, 2016 , ... Superior Controls, ... solutions, today announced the company has successfully completed its 50th consecutive audit. ... control systems integration services to leading companies in life sciences, food and beverage, ...
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Creative Medical ... Kesari , MD, PhD, FANA, FAAN to the Company,s ... neurology and clinical trials to assist the Company,s clinical ... stroke. The AmnioStem product is a universal donor stem cell ... activity in animal models of stroke 1 .  ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... development of precision treatments for neurodegenerative diseases, today announced the validated monoclonal ... the direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) in ...
Breaking Biology Technology:
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 ... is one of the most crucial aspects of recovery so we need to do ... serious health risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... friends sleep and find a Christmas present that could help them to manage their ... ...
(Date:11/29/2016)... 2016 Nearly one billion matches per second with ... ... DERMALOG is Germany's largest ... Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):